FOS and breast carcinoma: In addition, our study identified that ProLBS in combination with prebiotic FOS supplementation effected a reduction in level of circulating TNF-α [MD = −15.06; 95% CI: −23.20 to −6.91; p = 0.0003] in the population of breast cancer survivors.